- Trials with a EudraCT protocol (19)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (964)
19 result(s) found for: Xy.
Displaying page 1 of 1.
EudraCT Number: 2010-021790-37 | Sponsor Protocol Number: UK_S-H_08_0006 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Universitätsklinikum Schleswig-Holstein, Campus Lübeck | |||||||||||||
Full Title: Comparison of clinical and metabolic effects of testosterone and estradiol in adult gonadectomized patients with 46,XY DSD due to complete androgen insensitivity syndrome (CAIS) | |||||||||||||
Medical condition: The medical condition under investigation is complete androgen insensitivity syndrome (CAIS) in gonadectomized patients with 46,XY karyotype due to mutations of the androgen receptor, which lead to... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005166-12 | Sponsor Protocol Number: HMPL-004-US-02 | Start Date*: 2008-07-29 | |||||||||||
Sponsor Name:Hutchison MediPharma Enterprises Limited | |||||||||||||
Full Title: A Phase II, Randomized, Multi-Centre, Double-Blind, Placebo-Controlled Trial of HMPL-004 in Patients with Mild to Moderate Active Ulcerative Colitis with or without Mesalamine | |||||||||||||
Medical condition: active mild to moderate ulcerative colitis defined as a Mayo clinical score of 4-10 points | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000087-15 | Sponsor Protocol Number: CRd | Start Date*: 2012-03-30 |
Sponsor Name:FONDAZIONE NEOPLASIE SANGUE ONLUS | ||
Full Title: A PHASE II, MULTI-CENTER, OPEN LABEL STUDY OF CYCLOPHOSPHAMIDE IN MULTIPLE MYELOMA PATIENTS WITH BIOCHEMICAL PROGRESSION DURING LENALIDOMIDE-DEXAMETHASONE TREATMENT FOR RELAPSED/REFRACTORY MULTIPLE... | ||
Medical condition: RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-000287-34 | Sponsor Protocol Number: ARO-012 | Start Date*: 2017-05-30 | |||||||||||
Sponsor Name:Arog Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Trial of Crenolanib in Subjects with Advanced or Metastatic Gastrointestinal Stromal Tumors with a D842V Mutation in the PDGFRA Gene. | |||||||||||||
Medical condition: Advanced or metastatic gastrointestinal stromal tumor (GIST) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-007698-22 | Sponsor Protocol Number: R2-CHOP | Start Date*: 2008-07-10 |
Sponsor Name:GELARC | ||
Full Title: A PHASE IB/II STUDY OF ESCALATING DOSES OF REVLIMID IN ASSOCIATION WITH R-CHOP (R2-CHOP) IN THE TREATMENT OF B-CELL LYMPHOMA | ||
Medical condition: B cell lymphoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-003372-37 | Sponsor Protocol Number: ET11-072 | Start Date*: 2014-06-04 | |||||||||||
Sponsor Name:CENTRE LEON BERARD | |||||||||||||
Full Title: An international, randomized, open-label Phase I/II study of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent or refractory medulloblastoma pre... | |||||||||||||
Medical condition: Recurrent, progressive or refractory medulloblastoma with activation of the SHH pathway | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016197-33 | Sponsor Protocol Number: 3.1 | Start Date*: 2010-02-25 | |||||||||||
Sponsor Name:Celltrion, Inc. | |||||||||||||
Full Title: A Double-blind, Randomised, Parallel Group, Phase III Study to Demonstrate Equivalent Efficacy and Comparable Safety of CT-P6 and Herceptin, Both in Combination with Paclitaxel, in Patients with Me... | |||||||||||||
Medical condition: Metastatic breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: AT (Completed) PL (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014463-39 | Sponsor Protocol Number: 1.1 | Start Date*: 2009-12-01 | |||||||||||
Sponsor Name:Celltrion, Inc. | |||||||||||||
Full Title: A Double-blind Randomised, Parallel Phase I/IIb Study to Evaluate Initial Safety and Efficacy, Comparative Pharmacokinetics and Immunogenicity for CT-P6 and Herceptin in Metastatic Breast Cancer | |||||||||||||
Medical condition: Metastatic breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: LV (Completed) BG (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000362-53 | Sponsor Protocol Number: QOLONERev2MDS | Start Date*: 2016-11-23 | ||||||||||||||||
Sponsor Name:ASSOCIAZIONE QOL-ONE | ||||||||||||||||||
Full Title: Efficacy of eltrombopag plus lenalidomide combination therapy in patients with IPSS low and intermediate-risk myelodysplastic syndrome with isolated del5q: a multicenter, randomized, double-blind, ... | ||||||||||||||||||
Medical condition: Adult subject (18 years of age older) with low or intermediate-1 IPSS risk MDS with isolated del(5q) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) GR (Prematurely Ended) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011793-14 | Sponsor Protocol Number: LENAGEM-PANC | Start Date*: 2009-10-06 | ||||||||||||||||
Sponsor Name:Karolinska Institute/Hospital | ||||||||||||||||||
Full Title: Phase I/II study of lenalidomide and gemcitabine as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. | ||||||||||||||||||
Medical condition: Advanced pancreatic cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022253-42 | Sponsor Protocol Number: CTU10.041/BRd | Start Date*: 2012-02-14 | |||||||||||
Sponsor Name:Kantonsspital St. Gallen | |||||||||||||
Full Title: An open, multicentric phase II trial to evaluate the efficacy and safety of Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line therapy for patients with relapsed or refracto... | |||||||||||||
Medical condition: First relapsed or refractory multiple myeloma (including relapse after high dose chemotherapy followed by autologous stem cell transplantation) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-005393-22 | Sponsor Protocol Number: RETIRD04 | Start Date*: 2016-11-03 | ||||||||||||||||
Sponsor Name:QLT Inc. | ||||||||||||||||||
Full Title: A Study of the Efficacy and Safety of QLT091001 in Subjects with Inherited Retinal Disease (IRD) Caused by Mutation in Retinal Pigment Epithelium Protein 65 (RPE65) or Lecithin:Retinol Acyltransfer... | ||||||||||||||||||
Medical condition: Inherited retinal disease (IRD) phenotypically diagnosed as Leber congenital amaurosis (LCA) or retinitis pigmentosa (RP) caused by mutations in the retinal pigment epithelium protein 65 (RPE65) or... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Prematurely Ended) NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005473-22 | Sponsor Protocol Number: 20101-23101 | Start Date*: 2013-09-26 | |||||||||||
Sponsor Name:EORTC | |||||||||||||
Full Title: Very early FDG-PET/CT-response adapted therapy for advanced stage Hodgkin Lymphoma, a randomized phase III non-inferiority study of the EORTC Lymphoma Group. | |||||||||||||
Medical condition: Advanced stage Hodgkin's lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002430-21 | Sponsor Protocol Number: PALOMA | Start Date*: 2019-07-17 | ||||||||||||||||
Sponsor Name:GWT-TUD GmbH | ||||||||||||||||||
Full Title: Primary comparison of Liposomal Anthracycline based treatment versus conventional care strategies prior to allogeneic stem cell transplantation in patients with higher risk MDS and oligoblastic AML | ||||||||||||||||||
Medical condition: Untreated patients with higher risk MDS and oligoblastic AML eligible and intended for allogeneic HCT within the next 6 months | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Ongoing) AT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002841-39 | Sponsor Protocol Number: GINECO-OV-222 | Start Date*: 2013-10-07 | |||||||||||
Sponsor Name:ARCAGY GINECO | |||||||||||||
Full Title: A randomized, open label, phase II trial of bevacizumab plus weekly paclitaxel followed by bevacizumab monotherapy maintenance versus weekly paclitaxel followed by observation in patients with rela... | |||||||||||||
Medical condition: Patients with an histologically confirmed diagnosis of ovarian sex-cord stromal tumor in relapse after a platinum-based chemotherapy. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000200-10 | Sponsor Protocol Number: GFM-DAC-CMML | Start Date*: 2014-08-12 | |||||||||||
Sponsor Name:Groupe Francophone des Myélodysplasies (GFM) | |||||||||||||
Full Title: A Randomized Phase III study of Decitabine (DAC) with or without Hydroxyurea (HY) versus HY in patients with advanced proliferative Chronic Myelomonocytic Leukemia (CMML) | |||||||||||||
Medical condition: Proliferative Chronic Myelomonocytic Leukemia (CMML) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016871-32 | Sponsor Protocol Number: 0911001 | Start Date*: 2010-06-28 | ||||||||||||||||
Sponsor Name:CHU de TOULOUSE | ||||||||||||||||||
Full Title: A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplan... | ||||||||||||||||||
Medical condition: Myeloma, Multiple Myeloma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) BE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-003694-27 | Sponsor Protocol Number: AC-055-303 | Start Date*: 2011-11-17 | |||||||||||
Sponsor Name:Actelion Pharmaceuticals Ltd | |||||||||||||
Full Title: SERAPHIN-OL: Study with an ERA in Pulmonary arterial Hypertension to Improve cliNical outcome (Open Label) Long-term single-arm open-label extension study of the SERAPHIN study, to assess the safe... | |||||||||||||
Medical condition: symptomatic pulmonary arterial hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NL (Completed) FR (Completed) FI (Prematurely Ended) SE (Completed) AT (Completed) BE (Completed) DK (Completed) SK (Completed) PT (Prematurely Ended) IT (Completed) PL (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002440-14 | Sponsor Protocol Number: AC-055-302 | Start Date*: 2008-05-15 | |||||||||||
Sponsor Name:Actelion Pharmaceuticals Ltd. | |||||||||||||
Full Title: A multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, Phase III study to assess the effects of ACT-064992 on morbidity and mortality in patients with symptomati... | |||||||||||||
Medical condition: To assess the effects of ACT-064992 on morbidity and mortality in patients with symptomatic pulmonary arterial hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) DE (Completed) NL (Completed) FR (Completed) FI (Completed) SE (Completed) AT (Completed) DK (Completed) SK (Completed) PT (Prematurely Ended) IT (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.